Junlin Zhuo

Junlin Zhuo

Auto-generated profile, based on publicly available information

Junlin Zhuo

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in ACS Chemical Biology
Verified
Journal Article
Closed access
MDMorgan Dasovich
Morgan Dasovich
JZJunlin Zhuo
Junlin Zhuo
JGJack A. Goodman
Jack A. Goodman
ATAjit Thomas
Ajit Thomas
RMRobert Lyle McPherson
Robert Lyle McPherson
ALAnthony K. L. Leung
Anthony K. L. Leung

3 March 2026 in Nature Immunology
Verified
Journal Article
Open access
KFKatie Fisher
Katie Fisher
MGMauro A. Garcia
Mauro A. Garcia
GFGiacomo S. Frattari
Giacomo S. Frattari
CNChloé Naasz
Chloé Naasz
JZJunlin Zhuo
Junlin Zhuo
OSOle S. Søgaard
Ole S. Søgaard
Antiretroviral therapy (ART) interruption typically leads to rapid HIV-1 viral rebound in people with HIV-1. To develop an HIV-1 cure, insight into immunological mechanisms capable of preventing HIV-1 viral rebound is urgently needed. Here, we describe three exceptional post-intervention controllers (PICs) who maintained ART-free virological control for >6.5 years (ongoing), >7.5 years (ongoing) and 2.5 years following administration of broadly neutralizing antibodies. PICs had quantifiable genetically intact/inducible infectious proviral reservoirs that were increasingly clonal and located in nongenic/centromeric chromosomal regions, indicating immune-mediated selection. Potent autologous neutralizing antibodies and polyfunctional HIV-1-specific CD4 + and CD8 + T cell responses, pre-programmed for antigen response, were present before, and persisted during, ART interruption. In one PIC, viral rebound following 2.5 years of ART-free control was associated with accumulated viral mutations that resulted in escape from neutralizing antibody and T cell responses. Collectively, our findings support developing HIV-1 curative strategies aimed at enhancing pre-existing adaptive immune responses.

1 January 2026 in RSC Chemical Biology
Verified
Journal Article
Open access
BBBanhi Biswas
Banhi Biswas
JZJunlin Zhuo
Junlin Zhuo
Jürgen BoschJürgen Bosch
Jürgen Bosch
HVHien Vu
Hien Vu
LPLorencia Pak
Lorencia Pak
ALAnthony K. L. Leung
Anthony K. L. Leung
GS-441524, the parent nucleoside of remdesivir, engages the SARS-CoV-2 macrodomain (Mac1) in cells, and its diphosphate metabolite exhibits enhanced inhibitory activity.